The latest price target for BriaCell Therapeutics (NASDAQ:BCTX) was reported by HC Wainwright & Co. on October 3, 2024. The analyst firm set a price target for $15.00 expecting BCTX to rise to within 12 months (a possible 1462.50% upside). 6 analyst firms have reported ratings in the last year.

The latest analyst rating for BriaCell Therapeutics (NASDAQ:BCTX) was provided by HC Wainwright & Co., and BriaCell Therapeutics reiterated their buy rating.

There is no last upgrade for BriaCell Therapeutics

There is no last downgrade for BriaCell Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BriaCell Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BriaCell Therapeutics was filed on October 3, 2024 so you should expect the next rating to be made available sometime around October 3, 2025.

While ratings are subjective and will change, the latest BriaCell Therapeutics (BCTX) rating was a reiterated with a price target of $15.00 to $15.00. The current price BriaCell Therapeutics (BCTX) is trading at is $0.96, which is out of the analyst’s predicted range.